Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.51 |
| ▸ | TUBB | P07437 | 4/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.51 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343736 | 0.93 | TUBB1 (0.58) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6346985 | 0.91 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1USP2RAB9AHSD17B10 | |
| SCHEMBL6347233 | 0.89 | TUBB1 (0.57) | SMN1; SMN2NPC1USP2RAB9AHSD17B10 | |
| SCHEMBL6346881 | 0.88 | CREBBP (0.55) | SMN1; SMN2NPC1USP2RAB9AHSD17B10 | |
| SCHEMBL6356792 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1USP2RAB9AHSD17B10 | |
| SCHEMBL6355432 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1USP2RAB9AHSD17B10 | |
| SCHEMBL6347272 | 0.86 | NPC1 (0.51) | SMN1; SMN2NPC1USP2RAB9AHSD17B10 | |
| SCHEMBL6357323 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1USP2RAB9AHSD17B10 | |
| SCHEMBL6350134 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1USP2RAB9AHSD17B10 | |
| SCHEMBL6349164 | 0.85 | MAPT (0.46) | SMN1; SMN2NPC1RAB9ATUBB1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2005-09-15 | — | — | US | disclosed |
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | MCL1, ENPP1, MYC | SMN1; SMN2 1350/4885NPC1 2998/4885USP2 2948/4885 |
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | SMN1; SMN2 1350/4885NPC1 2998/4885USP2 2948/4885 |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | SMN1; SMN2 1350/4885NPC1 2998/4885USP2 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.